Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.55 |
| ▸ | MIF | P14174 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.49 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.49 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.49 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | F13A1 | P00488 | 1/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | TACR2 | P21452 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158877 | 0.95 | CALM1 (0.53) | CALM1MIFTSHREPHX2ESR1 | |
| SCHEMBL31522355 | 0.93 | ACHE (0.55) | CALM1MIFEPHX2ESR1KDM4E | |
| SCHEMBL10686548 | 0.93 | ACHE (0.55) | CALM1MIFEPHX2ESR1KDM4E | |
| SCHEMBL13903181 | 0.93 | ACHE (0.55) | CALM1MIFEPHX2ESR1KDM4E | |
| SCHEMBL22921868 | 0.92 | TSHR (0.58) | TSHREPHX2CYP4F2CYP4A11ALDH1A1 | |
| 4-Hydroxyhydrocinnamic Acid Methyl Ester SCHEMBL95254 | 0.89 | HDAC2 (0.53) | CALM1TSHRESR1CYP19A1ESR2 | |
| 4-Hydroxyhydrocinnamic Acid Methyl Ester SCHEMBL30611554 | 0.87 | HDAC2 (0.51) | CALM1TSHRESR1CYP19A1ESR2 | |
| SCHEMBL3456495 | 0.85 | CYP4A11 (0.53) | TSHREPHX2CYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL1928824 | 0.85 | PLAAT3 (0.51) | TSHREPHX2PLAAT3PLAAT5PLAAT2 | |
| SCHEMBL1866015 | 0.85 | CYP4A11 (0.50) | TSHREPHX2CYP4F2CYP4A11ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-11 | — | — | US | disclosed |
| EP-4519259-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4519260-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XDEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024263781-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | TREELINE BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
| WO-2023215482-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215471-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0635007-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF TYPE II-DIABETES | SMITHKLINE BEECHAM PLC (GB) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993021166-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF TYPE II-DIABETES | SMITHKLINE BEECHAM PLC (GB) | 1993-10-28 | — | — | WO | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4761420-A | CARDIOVASCULAR DISORDERS | LABORATOIRES SYNTEX S.A. (FR) | 1988-08-02 | — | — | US | disclosed |
| EP-0249245-A2 | Antihypertensive dihydropyridine derivatives | LABORATOIRES SYNTEX S.A. (FR) | 1987-12-16 | — | — | EP | disclosed |
| US-4672071-A | Antihypertensive dihydropyridine compositions, optical isomers and intermediates | SYNTEX (U.S.A.) INC. (US) | 1987-06-09 | — | — | US | disclosed |
| EP-0191448-A2 | Antihypertensive dihydropyridine derivatives | SYNTEX (U.S.A.) INC. (US) | 1986-08-20 | — | — | EP | disclosed |
| US-4595690-A | Hypotensive agents | SYNTEX (U.S.A.) INC. (US) | 1986-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | CALM1 3697/4885MIF 3556/4885TRPV1 375/4885 |
| US-20250282771-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2, BCL2L10, BCL2L1 | CALM1 2258/4885MIF 3610/4885TRPV1 4603/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | CALM1 1855/4885MIF 3950/4885TRPV1 4649/4885 |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | CALM1 1855/4885MIF 3950/4885TRPV1 4649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.